These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 25453096)

  • 1. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
    Samanta D; Gilkes DM; Chaturvedi P; Xiang L; Semenza GL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5429-38. PubMed ID: 25453096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
    Takahashi K; Tanaka M; Inagaki A; Wanibuchi H; Izumi Y; Miura K; Nagayama K; Shiota M; Iwao H
    Int J Oncol; 2013 Dec; 43(6):1985-91. PubMed ID: 24126575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
    Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
    Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
    Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
    Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
    Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy induces enrichment of CD47
    Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 14. The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells.
    Chen M; He M; Song Y; Chen L; Xiao P; Wan X; Dai F; Shen P
    Int J Mol Med; 2014 Jul; 34(1):276-82. PubMed ID: 24804820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S; Yao Y; Yao M; Fu P; Wang W
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
    Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
    Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
    Lu H; Tran L; Park Y; Chen I; Lan J; Xie Y; Semenza GL
    Cancer Res; 2018 Aug; 78(15):4191-4202. PubMed ID: 29880481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment.
    Chaturvedi P; Gilkes DM; Takano N; Semenza GL
    Proc Natl Acad Sci U S A; 2014 May; 111(20):E2120-9. PubMed ID: 24799675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
    El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
    PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro.
    Tanaka T; Ikegami Y; Nakazawa H; Kuriyama N; Oki M; Hanai J; Sukhatme VP; Kaneki M
    J Cell Physiol; 2017 Jan; 232(1):192-201. PubMed ID: 27137755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.